eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Original paper

Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland

Anna Sztafińska
1
,
Mikołaj Gwardys
2
,
Daniela Podlecka
1
,
Ewa Mospinek
1
,
Iwona Stelmach
1

1.
Department of Paediatrics and Allergy, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
2.
Department of Paediatrics and Immunology with Nephrology Unit, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
Adv Dermatol Allergol 2021; XXXVIII (3): 427–432
Online publish date: 2021/07/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Omalizumab has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with moderate or severe persistent allergic asthma.

Aim
To evaluate effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma.

Material and methods
Seventeen children and adolescents aged 8–16, treated with omalizumab from 2011 until now, were enrolled into the retrospective, open, uncontrolled, observational study. The effectiveness of therapy, asthma control, quality of life, exacerbation rate, corticosteroid use, were assessed after 16, 52 and 104 weeks of treatment and after omalizumab cessation.

Results
The response to treatment was assessed as excellent (9 patients) and good (6 patients), according to global evaluation of treatment effectiveness (GETE). A statistically significant decrease in use of oral corticosteroids (OCS) and leukotriene receptor antagonists (LTRAs) was observed. The doses of inhaled corticosteroids (ICS) decreased significantly (the mean dose of ICS converted to a dose of budesonide before treatment was 1503.53 μg/day versus 903.53 μg after discontinuation). The mean asthma control questionnaire (ACQ) value decreased from 2.10 to 0.84 points and the mean mini asthma quality of life questionnaire (miniAQLQ) outcome increased from 4.37 to 6.1 points. The mean number of exacerbations decreased from 5.59 to 0.53 per year.

Conclusions
Our results are supportive of the existing evidence that omalizumab therapy improves asthma control, reduces OCS and ICS use, decreases exacerbations in children and adolescents with severe/moderate uncontrolled allergic asthma.

keywords:

asthma, omalizumab, anti-IgE therapy, children

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe